Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial.

ABSTRACT:

Objective

To show non-inferiority of trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of severe infections due to meticillin resistant Staphylococcus aureus (MRSA).

Design

Parallel, open label, randomised controlled trial.

Setting

Four acute care hospitals in Israel.

Participants

Adults with severe infections caused by MRSA susceptible to trimethoprim-sulfamethoxazole and vancomycin. Patients with left sided endocarditis, meningitis, chronic haemodialysis, and prolonged neutropenia were excluded.

Interventions

Trimethoprim-sulfamethoxazole 320 mg/1600 mg twice daily versus vancomycin 1 g twice daily for a minimum of seven days and then by indication.

Main outcome measures

The primary efficacy outcome was treatment failure a

SUBMITTER: Paul M 

PROVIDER: S-EPMC4431679 | biostudies-literature | 2015 May

REPOSITORIES: biostudies-literature